Share-based Payment Arrangement, Expense in USD of XBiotech Inc. from 2013 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
XBiotech Inc. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from 2013 to Q3 2025.
  • XBiotech Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $24,000.000, a 93.4% decline year-over-year.
  • XBiotech Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $4,088,000.000, a 125% increase year-over-year.
  • XBiotech Inc. annual Share-based Payment Arrangement, Expense for 2024 was $1,753,000.000, a 46.3% decline from 2023.
  • XBiotech Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3,262,000.000, a 35.6% decline from 2022.
  • XBiotech Inc. annual Share-based Payment Arrangement, Expense for 2022 was $5,062,000.000, a 13.4% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

XBiotech Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $4,088,000 $24,000 -$341,000 -93.4% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025
Q2 2025 $4,429,000 $107,000 -$272,000 -71.8% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025
Q1 2025 $4,701,000 $3,329,000 +$2,948,000 +7.7% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025
Q4 2024 $1,753,000 $628,000 -$60,000 -8.7% 01 Oct 2024 31 Dec 2024 10-K 18 Mar 2025
Q3 2024 $1,813,000 $365,000 -$590,000 -61.8% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025
Q2 2024 $2,403,000 $379,000 -$535,000 -58.5% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025
Q1 2024 $2,938,000 $381,000 -$324,000 -46% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025
Q4 2023 $3,262,000 $688,000 -$350,000 -33.7% 01 Oct 2023 31 Dec 2023 10-K 18 Mar 2025
Q3 2023 $3,612,000 $955,000 -$173,000 -15.3% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024
Q2 2023 $3,785,000 $914,000 -$534,000 -36.9% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024
Q1 2023 $4,319,000 $705,000 -$743,000 -51.3% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2023
Q4 2022 $5,062,000 $1,038,000 -$316,000 -23.3% 01 Oct 2022 31 Dec 2022 10-K 15 Mar 2024
Q3 2022 $5,378,000 $1,128,000 -$5,000 -0.44% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 $5,383,000 $1,448,000 +$408,000 +39.2% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023
Q1 2022 $4,975,000 $1,448,000 +$512,000 +54.7% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023
Q4 2021 $4,463,000 $1,354,000 -$1,440,000 -51.5% 01 Oct 2021 31 Dec 2021 10-K 15 Mar 2023
Q3 2021 $5,903,000 $1,133,000 -$2,022,000 -64.1% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022
Q2 2021 $7,925,000 $1,040,000 -$2,136,000 -67.3% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022
Q1 2021 $10,061,000 $936,000 -$2,520,000 -72.9% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022
Q4 2020 $12,581,000 $2,794,000 +$1,289,000 +85.6% 01 Oct 2020 31 Dec 2020 10-K 15 Mar 2022
Q3 2020 $11,292,000 $3,155,000 +$2,358,000 +3% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021
Q2 2020 $8,934,000 $3,176,000 +$2,690,000 +5.5% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021
Q1 2020 $6,244,000 $3,456,000 +$2,886,000 +5.1% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021
Q4 2019 $3,358,000 $1,505,000 +$1,031,000 +2.2% 01 Oct 2019 31 Dec 2019 10-K 15 Mar 2022
Q3 2019 $2,327,000 $797,000 +$358,000 +81.5% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020
Q2 2019 $1,969,000 $486,000 -$151,000 -23.7% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020
Q1 2019 $2,120,000 $570,000 +$460,000 +4.2% 01 Jan 2019 31 Mar 2019 10-Q 09 May 2019
Q4 2018 $1,660,000 $474,000 +$65,000 +15.9% 01 Oct 2018 31 Dec 2018 10-K 16 Mar 2021
Q3 2018 $1,595,000 $439,000 -$6,000 -1.3% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019
Q2 2018 $1,601,000 $637,000 -$261,000 -29.1% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019
Q1 2018 $1,862,000 $110,000 -$614,000 -84.8% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019
Q4 2017 $2,476,000 $409,000 -$1,123,000 -73.3% 01 Oct 2017 31 Dec 2017 10-K 16 Mar 2020
Q3 2017 $3,599,000 $445,000 -$681,000 -60.5% 01 Jul 2017 30 Sep 2017 10-Q 31 Oct 2018
Q2 2017 $4,280,000 $898,000 -$200,000 -18.2% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018
Q1 2017 $4,480,000 $724,000 -$1,093,000 -60.2% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018
Q4 2016 $5,573,000 $1,532,000 +$480,000 +45.6% 01 Oct 2016 31 Dec 2016 10-K/A 15 Mar 2019
Q3 2016 $5,093,000 $1,126,000 +$240,000 +27.1% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017
Q2 2016 $4,853,000 $1,098,000 -$149,000 -11.9% 01 Apr 2016 30 Jun 2016 10-Q 08 Aug 2017
Q1 2016 $5,002,000 $1,817,000 +$595,000 +48.7% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017
Q4 2015 $4,407,000 $1,052,000 -$996,000 -48.6% 01 Oct 2015 31 Dec 2015 10-K 16 Mar 2018
Q3 2015 $5,403,000 $886,000 -$1,638,000 -64.9% 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016
Q2 2015 $7,041,000 $1,247,000 +$641,000 +1.1% 01 Apr 2015 30 Jun 2015 10-Q 12 Aug 2016
Q1 2015 $6,400,000 $1,222,000 -$620,000 -33.7% 01 Jan 2015 31 Mar 2015 10-Q 13 May 2016
Q4 2014 $7,020,000 $2,048,000 01 Oct 2014 31 Dec 2014 10-K 16 Mar 2017
Q3 2014 $2,524,000 01 Jul 2014 30 Sep 2014 10-Q 13 Nov 2015
Q2 2014 $606,000 01 Apr 2014 30 Jun 2014 10-Q 14 Aug 2015
Q1 2014 $1,842,000 01 Jan 2014 31 Mar 2014 10-Q 18 Jun 2015

XBiotech Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $1,753,000 -$1,509,000 -46.3% 01 Jan 2024 31 Dec 2024 10-K 18 Mar 2025
2023 $3,262,000 -$1,800,000 -35.6% 01 Jan 2023 31 Dec 2023 10-K 18 Mar 2025
2022 $5,062,000 +$599,000 +13.4% 01 Jan 2022 31 Dec 2022 10-K 15 Mar 2024
2021 $4,463,000 -$8,118,000 -64.5% 01 Jan 2021 31 Dec 2021 10-K 15 Mar 2023
2020 $12,581,000 +$9,223,000 +2.7% 01 Jan 2020 31 Dec 2020 10-K 15 Mar 2022
2019 $3,358,000 +$1,698,000 +1% 01 Jan 2019 31 Dec 2019 10-K 15 Mar 2022
2018 $1,660,000 -$816,000 -33% 01 Jan 2018 31 Dec 2018 10-K 16 Mar 2021
2017 $2,476,000 -$3,097,000 -55.6% 01 Jan 2017 31 Dec 2017 10-K 16 Mar 2020
2016 $5,573,000 +$1,166,000 +26.5% 01 Jan 2016 31 Dec 2016 10-K/A 15 Mar 2019
2015 $4,407,000 -$2,613,000 -37.2% 01 Jan 2015 31 Dec 2015 10-K 16 Mar 2018
2014 $7,020,000 +$6,281,000 +8.5% 01 Jan 2014 31 Dec 2014 10-K 16 Mar 2017
2013 $739,000 01 Jan 2013 31 Dec 2013 10-K 15 Apr 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.